Tomahawk, WI 09/02/2014 (Basicsmedia) – Dubbed as the most severe and deadly outbreak, the Ebola menace in West Africa has caught the attention of GlaxoSmithKline plc (ADR) (NYSE:GSK) and National institute of health. CNBC’s Meg Tirrell reports that NIH and GlaxoSmithKline have partnered to develop a vaccine that is said to have had immense success in primates, but yet to be tested in Humans.

The studies are to be used to ascertain whether the vaccine is safe and also its ability to prompt an immune response, able to combat the Ebola virus. No humans are to be infected’ with the Ebola virus during the course of the study.

“Testing in people is scheduled to start next week on an Ebola vaccine being co-developed by GlaxoSmithKline plc (ADR) (NYSE:GSK) and the National institute of health. Results are expected’ by the end of this year,” said Mrs. Tirrell.

The WHO has outlined a roadmap plan that is to be used to stop the spread of the disease to unaffected places with 20,000 people already thought to have been’ infected. The organization has also set aside $490 million that will be used to combat further spread of the disease while accelerating the development of vaccines and cure that are to be’ used as countermeasures for the disease.

GlaxoSmithKline plc (ADR) (NYSE:GSK)is to carry out tests then leave it to the WHO to determine whether the vaccine will go into phase two of the trial or it will be’ used in high-risk areas. GlaxoSmithKline has already indicated that it will begin the production of additional 10,000 doses after receiving funding from the Wellcome Trust Foundation. The doses will be made available should the ongoing tests turnout positive.

“What we are really looking for is for any adverse side effects as well as is it producing the immune response that we need to help control and prevent the Ebola disease. That should happen at the end of 2014 and then it will be up to the world health organization what to do after that, “said Donna Altenpohl, GlaxoSmithKline plc (ADR) (NYSE:GSK) Public Policy Vice President.

Commercial viability of the vaccine remains uncertain as very few pharmaceutical are currently developing a vaccine for the disease.

DISCLAIMER: This content is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.